Introduction
Renagel (Sevelamer Hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. It comes in 800 mg and 400 mg Tablets, with a dosing regimen that includes titration of dose for serum phosphorus control.
Overview of Renagel
Renagel (Sevelamer Hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. It is available in tablet form with dosages of 800 mg and 400 mg. The dosage must be titrated based on serum phosphorus levels to effectively control phosphorus levels in the body.
Indications
Renagel (Sevelamer Hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. It is important to titrate the dose based on serum phosphorus levels to achieve the target range for efficient phosphorus control.
Control of Serum Phosphorus in CKD Patients
Renagel (Sevelamer Hydrochloride) is prescribed to regulate serum phosphorus levels in chronic kidney disease (CKD) patients undergoing dialysis. The dosage regimen involves adjusting the dose incrementally by 400-800 mg per meal over 2-week intervals to maintain target serum phosphorus levels.
Dosage Forms
Renagel is available in tablet form, with dosages of 800 mg and 400 mg. The 800 mg tablets are oval, film-coated, and contain sevelamer hydrochloride along with various excipients. The tablets are designed to be swallowed whole and are imprinted for identification purposes.
800 mg and 400 mg Tablets
Renagel is available in tablet form in dosages of 800 mg and 400 mg. The 800 mg tablets are oval, film-coated, compressed tablets imprinted with ″RENAGEL 800,″ containing sevelamer hydrochloride and various excipients. Similarly, the 400 mg tablets are also film-coated and designed to be taken orally. The tablets should be swallowed whole with meals as prescribed by the healthcare provider;
Dosage and Administration
Renagel dosing is based on titration, starting at 800 to 1600 mg per meal with adjustments every 2 weeks. The aim is to reach target serum phosphorus levels by incrementally increasing the dose. It is crucial to follow the prescribed dosing regimen diligently.
Titration of Dose for Serum Phosphorus Control
Dosing adjustments for Renagel involve titrating the dose by increasing it from 400-800 mg per meal at 2-week intervals as necessary to reach target serum phosphorus levels. This titration process enables the healthcare provider to regulate phosphorus levels effectively in CKD patients on dialysis.
Contraindications
Renagel is contraindicated in patients with bowel obstruction or known hypersensitivity to sevelamer hydrochloride. It is crucial to avoid the use of Renagel in these individuals due to potential adverse reactions or complications.
Patients with Bowel Obstruction or Hypersensitivity
Renagel is contraindicated in patients with bowel obstruction or known hypersensitivity to sevelamer hydrochloride. It is crucial to avoid the use of Renagel in these individuals due to potential adverse reactions or complications that may arise.
Warnings and Precautions
When considering the use of Renagel, it is important to take caution in patients with gastrointestinal disorders. Monitoring for any potential complications related to the gastrointestinal system is crucial to ensure the safe and effective use of this medication.
Considerations for Gastrointestinal Disorders
When using Renagel, special considerations should be made for patients with gastrointestinal disorders. Monitoring for any signs of gastrointestinal complications and adjusting the treatment plan accordingly is essential to ensure the well-being of the patient.
Drug Interactions
Interaction warnings are noted between Renagel and specific medications such as Ciprofloxacin and Mycophenolate Mofetil. Due to these potential interactions, it is crucial to administer these drugs separately to avoid any adverse effects.
Possible Interactions with Ciprofloxacin and Mycophenolate Mofetil
Sevelamer has demonstrated interactions with ciprofloxacin and mycophenolate mofetil. Due to these interactions, it is advised to administer ciprofloxacin and mycophenolate mofetil separately from Renagel to prevent potential drug interactions and ensure the effectiveness of each medication.
Adverse Reactions
When using Renagel, potential gastrointestinal adverse events may occur. Monitoring for these adverse reactions is essential to ensure the patient’s well-being and address any unexpected symptoms promptly.
Potential Gastrointestinal Adverse Events
When using Renagel, potential gastrointestinal adverse events may occur. Monitoring for these adverse reactions is crucial to ensure the patient’s well-being and address any unexpected symptoms promptly to prevent further complications.
Leave a Reply